8.200USD+8.200After-hours 07/30, 20:00 (ET)
530.84MMarket Cap
LossP/E TTM
Key Figures
8.180Open
8.340High
740.47KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.15%Turnover Ratio
8.200Prev. Close
8.090Low
4.83MTurnover
LossP/E Static
1.37P/B
0.00%Div Yield TTM
-26.85%ROA
14.51052wk High
1.34Volume Ratio
-198.90MNet Profit
64.50MShares
-3.1831EPS TTM
1.76Beta
-42.28%ROE
6.05552wk Low
3.05%Amplitude
100.00%Gross Margin
530.84MMarket Cap
-0.41Reward/Risk
3.20%Risk Rate
Currency: USD Updated: 2026-07-29 Key Insights
Arvinas Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 147 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.79.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Arvinas Inc Highlights
StrengthsRisks
Arvinas Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
27
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Arvinas Inc Info
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Ticker SymbolARVN
CompanyArvinas Inc
CEODr. John G. Houston, Ph.D.
Websitehttps://www.arvinas.com/
Shareholders
FAQs
What is the current price of Arvinas Inc (ARVN)?
The current price of Arvinas Inc (ARVN) is 8.23.
What is the symbol of Arvinas Inc?
The ticker symbol of Arvinas Inc is ARVN.
What is the 52-week high of Arvinas Inc?
The 52-week high of Arvinas Inc is 14.51.
What is the 52-week low of Arvinas Inc?
The 52-week low of Arvinas Inc is 6.05.
What is the market capitalization of Arvinas Inc?
The market capitalization of Arvinas Inc is 530.84M.
Is Arvinas Inc (ARVN) currently rated as Buy, Hold, or Sell?
According to analysts, Arvinas Inc (ARVN) has an overall rating of Buy, with a price target of 14.79.
What is the Earnings Per Share (EPS TTM) of Arvinas Inc (ARVN)?
The Earnings Per Share (EPS TTM) of Arvinas Inc (ARVN) is -1.14.
